{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/","result":{"pageContext":{"chapter":{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)","depth":2,"htmlHeader":"<!-- begin field 08285fb9-f0c2-4558-8ddb-59d15b4802a7 --><h2>When should I suspect a hyperglycaemic emergency?</h2><!-- end field 08285fb9-f0c2-4558-8ddb-59d15b4802a7 -->","summary":"","htmlStringContent":"<!-- begin item 8f6a2160-f0e7-4f6f-8a56-6a405255c07f --><!-- begin field fc3e0210-96f5-41ca-8d35-4ead5e4e440e --><p><strong>The hyperglycaemic complications of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/background-information/complications/\">diabetic ketoacidosis</a></strong><strong> (DKA) and <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/background-information/complications/\">hyperosmolar hyperglycaemic state</a></strong><strong> (HHS) can be life-threatening and require emergency hospital <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/management/management-adults/#managing-suspected-hyperglycaemic-emergencies-dka-hhs\">admission</a> if suspected.</strong></p><ul><li><strong>Suspect a diagnosis of DKA in a person with known diabetes or significant hyperglycaemia (blood glucose level greater than 11 mmol/L) <em>and</em> the following:</strong><ul><li>Clinical symptoms<ul><li>Polydipsia and polyuria.</li><li>Weight loss.</li><li>Abdominal pain, nausea and/or vomiting.</li><li>Shortness of breath.</li><li>Lethargy, drowsiness, and/or confusion.</li><li>A possible history of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/#precipitating-factors\">precipitating factor(s)</a>.</li></ul></li><li>Clinical signs<ul><li>Fruity smell of acetone on the breath.</li><li>Tachypnoea, acidotic breathing (deep sighing 'Kussmaul respiration').</li><li>Tachycardia, dehydration (may present with reduced skin turgor, sunken eyes, prolonged capillary refill time) or shock (tachycardia, hypotension, drowsiness, reduced urine output).</li></ul></li><li>Blood or urinary ketones<ul><li>In an adult, test for blood or urinary ketones, even if plasma glucose levels are near normal. </li><li>In a child or young person, test for blood ketones, even if plasma glucose levels are near normal. If this is not possible, arrange immediate admission to a hospital with acute paediatric facilities. </li><li>Note: ketones are high if urinary ketones are greater than 2+, or capillary blood ketones are above 3 mmol/L. Test for blood ketones using a ketone testing meter and strips. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insulin-therapy-in-type-2-diabetes/\">Insulin therapy in type 2 diabetes</a> for information on ketone testing meters and strips. </li><li>Note: urinary ketones must be read 15 seconds after the stick is dipped.</li></ul></li></ul></li><li><strong>Consider the possibility of DKA in all people with type 2 diabetes who are unwell, even with normal blood glucose levels.</strong><ul><li>Children and young people on insulin therapy may develop DKA with normal blood glucose levels, as may people using <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/prescribing-information/sglt-2-inhibitors/\">SGLT2 inhibitors</a>, and people with a history of alcohol excess and/or chronic liver disease.</li><li>Low blood ketone levels (less than 3 mmol/L) do not always exclude DKA.</li></ul></li><li><strong>Suspect a diagnosis of HHS if a person is unwell with severe hyperglycaemia (blood glucose level typically above 30 mmol/L) for several days and:</strong><ul><li>Clinical symptoms<ul><li>Disorientation, confusion, and/or drowsiness.</li><li>Polyuria and polydipsia.</li><li>Nausea.</li><li>A possible history of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/#precipitating-factors\">precipitating factor(s)</a>.</li></ul></li><li>Clinical signs<ul><li>Severe dehydration and hypovolaemia.</li></ul></li><li>No significant signs of ketosis, or blood or urinary ketones on testing.</li></ul></li></ul><!-- end field fc3e0210-96f5-41ca-8d35-4ead5e4e440e --><!-- end item 8f6a2160-f0e7-4f6f-8a56-6a405255c07f -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"0a5553ee-d163-5de5-8fc6-63db3179e704","slug":"precipitating-factors","fullItemName":"Precipitating factors","depth":3,"htmlHeader":"<!-- begin field f60b35c0-2ee1-4963-bf17-ac9f00f96610 --><h3>Precipitating factors</h3><!-- end field f60b35c0-2ee1-4963-bf17-ac9f00f96610 -->","summary":null,"htmlStringContent":"<!-- begin item c9d3ae1f-e938-4656-b3f4-8fc6177b6a78 --><!-- begin field b513ee4b-eb32-435b-a865-ac9f00f96610 --><ul><li><strong>Precipitating factors of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) include:</strong><ul><li>Infection.</li><li>Inadequate insulin or non-adherence with insulin treatment.</li><li>New onset of diabetes mellitus or other physiological stress (such as trauma or surgery).</li><li>Other medical conditions (such as hypothyroidism or pancreatitis). </li><li>Drugs (such as corticosteroids, diuretics, atypical antipsychotics, and sympathomimetic drugs such as salbutamol).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Wolfsdorf, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">French, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020b</a>]</p><!-- end field b513ee4b-eb32-435b-a865-ac9f00f96610 --><!-- end item c9d3ae1f-e938-4656-b3f4-8fc6177b6a78 -->","subChapters":[]},{"id":"3af5ec17-d2ac-5736-b46a-efba7e95d3fa","slug":"basis-for-recommendation-936","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field bd3e46c7-5ab7-4d91-bef2-326d4e9b146f --><h3>Basis for recommendation</h3><!-- end field bd3e46c7-5ab7-4d91-bef2-326d4e9b146f -->","summary":null,"htmlStringContent":"<!-- begin item 936efda5-244b-4626-b8c4-0d951d368db1 --><!-- begin field 20d09852-8d20-407a-ba33-53cc89786b7e --><p>The recommendations on diagnosis of hyperglycaemic emergencies are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020b</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Diabetic ketoacidosis and the hyperglycemic hyperosmolar state</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Wolfsdorf, 2018</a>], the British Society for Paediatric Endocrinology and Diabetes (BSPED) publication <em>Interim guideline for the management of children and young people under the age of 18 years with diabetic ketoacidosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety updates <em>SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2016</a>] and <em>SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2020</a>], and expert opinion in review articles on diabetic ketoacidosis (DKA) and hyperglycaemic hyperosmolar state (HHS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">French, 2019</a>], on SGLT-2 inhibitors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Morris, 2019</a>], and on sick-day rules [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Down, 2020</a>].</p><h4>When to suspect DKA</h4><ul><li>The information that DKA usually presents in people with diabetes with high blood glucose levels above 11 mmol/L is extrapolated from limited evidence and consensus opinion in the BSPED guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>].</li><li>The information on the clinical features suggesting a diagnosis of DKA is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020b</a>], the BSPED guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>], the ISPAD clinical practice consensus guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Wolfsdorf, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">French, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Down, 2020</a>].</li><li>The information on the definitions of high urinary ketone and capillary blood ketone levels is based on the BSPED guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>], the ISPAD clinical practice consensus guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Wolfsdorf, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Down, 2020</a>].<ul><li>CKS notes that the BSPED guideline recommends using near-patient testing for blood ketone level for the diagnosis of DKA. If this is not available, it suggests using urinary ketone levels to make the diagnosis.</li><li>The information that urinary ketones must be read 15 seconds after the stick is dipped is based on the BSPED guideline.</li></ul></li><li>The information that DKA may develop in people with diabetes with normal blood glucose levels is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020b</a>], and is extrapolated from limited evidence and consensus opinion in the BSPED guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>] and expert opinion in review articles, which note various potential causes of so-called 'euglycaemic DKA' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">French, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Morris, 2019</a>]. In addition, an MHRA drug safety update recommends stopping SGLT-2 inhibitors and checking blood ketone levels if there is acute serious illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2020</a>]. </li></ul><h4>When to suspect HHS</h4><ul><li>The information on the clinical features suggesting a diagnosis of HHS is based on the BSPED guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BSPED, 2020</a>], the ISPAD clinical practice consensus guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Wolfsdorf, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">French, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Down, 2020</a>].</li></ul><!-- end field 20d09852-8d20-407a-ba33-53cc89786b7e --><!-- end item 936efda5-244b-4626-b8c4-0d951d368db1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}